An assessment of intervention thresholds for very high fracture risk applied to the NOGG guidelines
暂无分享,去创建一个
J. Kanis | M. Lorentzon | L. Vandenput | H. Johansson | E. McCloskey | N. Harvey | E. Liu
[1] J. Kanis,et al. FRAX-based intervention thresholds in eight Eurasian countries: Armenia, Belarus, Georgia, Kazakhstan, the Kyrgyz Republic, Moldova, the Russian Federation, and Uzbekistan , 2021, Archives of Osteoporosis.
[2] J. Kanis,et al. Cost-effectiveness of romosozumab for the treatment of postmenopausal women with severe osteoporosis at high risk of fracture in Sweden , 2021, Osteoporosis International.
[3] J. Kanis,et al. The use of 2-, 5-, and 10-year probabilities to characterize fracture risk after a recent sentinel fracture , 2020, Osteoporosis International.
[4] J. Kanis,et al. Adjusting conventional FRAX estimates of fracture probability according to the recency of sentinel fractures , 2020, Osteoporosis International.
[5] P. Geusens,et al. Efficacy of teriparatide compared with risedronate on FRAX®-defined major osteoporotic fractures: results of the VERO clinical trial , 2020, Osteoporosis International.
[6] C. Cooper,et al. Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures , 2019, Osteoporosis International.
[7] J. Kanis,et al. Characteristics of recurrent fractures , 2018, Osteoporosis International.
[8] P. Geusens,et al. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial , 2017, The Lancet.
[9] J. Kanis,et al. FRAX-based intervention and assessment thresholds in seven Latin American countries , 2018, Osteoporosis International.
[10] A. Grauer,et al. Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis , 2017, The New England journal of medicine.
[11] C. Cooper,et al. UK clinical guideline for the prevention and treatment of osteoporosis , 2017, Archives of Osteoporosis.
[12] A. Grauer,et al. Romosozumab Treatment in Postmenopausal Women with Osteoporosis. , 2016, The New England journal of medicine.
[13] C. Cooper,et al. A systematic review of intervention thresholds based on FRAX , 2016, Archives of Osteoporosis.
[14] J. Kanis,et al. FRAX and the effect of teriparatide on vertebral and non-vertebral fracture , 2015, Osteoporosis International.
[15] J. Kanis,et al. Efficacy of weekly teriparatide does not vary by baseline fracture probability calculated using FRAX , 2015, Osteoporosis International.
[16] C. Cooper,et al. FRAX-based assessment and intervention thresholds—an exploration of thresholds in women aged 50 years and older in the UK , 2015, Osteoporosis International.
[17] M. Cowie. National Institute for Health and Care Excellence. , 2015, European heart journal.
[18] E. M. Lewiecki,et al. Clinician’s Guide to Prevention and Treatment of Osteoporosis , 2014, Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA.
[19] Naoto Endo,et al. Japanese 2011 guidelines for prevention and treatment of osteoporosis—executive summary , 2012, Archives of Osteoporosis.
[20] T. Sone,et al. Randomized Teriparatide [human parathyroid hormone (PTH) 1-34] Once-Weekly Efficacy Research (TOWER) trial for examining the reduction in new vertebral fractures in subjects with primary osteoporosis and high fracture risk. , 2012, The Journal of clinical endocrinology and metabolism.
[21] C. Cooper,et al. A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis , 2012, Osteoporosis International.
[22] C. Cooper,et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women , 2008, Osteoporosis International.
[23] J. Kanis,et al. Case finding for the management of osteoporosis with FRAX®—assessment and intervention thresholds for the UK , 2008, Osteoporosis International.
[24] C. Cooper,et al. The cost-effectiveness of alendronate in the management of osteoporosis. , 2008, Bone.
[25] J. Reginster,et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. , 2001, The New England journal of medicine.